Abcellera Biologics Inc Total Assets
Abcellera Biologics Inc total assets. Based on the latest financial reports, Abcellera Biologics Inc (ABCL) holds total assets worth $1.31 Billion USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see ABCL company net worth for the company's overall valuation and market capitalisation.
Total Assets of Abcellera Biologics Inc (2018–2025)
Total assets of Abcellera Biologics Inc from 2018 to 2025. This chart illustrates how Abcellera Biologics Inc's total assets have evolved over time, based on quarterly financial data. See Abcellera Biologics Inc (ABCL) stock price for real-time trading data and today's change.
Abcellera Biologics Inc - Asset Composition Analysis
Abcellera Biologics Inc Total Assets Breakdown (December 2025)
Abcellera Biologics Inc total assets breakdown as of December 2025. Abcellera Biologics Inc's total assets of $1.31 Billion consist of 53.7% current assets and 46.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.5% |
| Accounts Receivable | $153.40 Million | 11.3% |
| Inventory | $6.34 Million | 0.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $38.38 Million | 2.8% |
| Goodwill | $47.81 Million | 3.5% |
Asset Composition Trend (2018–2025)
This chart illustrates how Abcellera Biologics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ABCL working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abcellera Biologics Inc's current assets represent 53.7% of total assets in 2025, a decrease from 70.6% in 2018.
- Cash Position: Cash and equivalents constituted 9.5% of total assets in 2025, down from 48.6% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is accounts receivable at 11.3% of total assets.
Abcellera Biologics Inc Competitors by Total Assets
Key competitors of Abcellera Biologics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Abcellera Biologics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.77 | 11.07 | 16.22 |
| Quick Ratio | 12.63 | 11.07 | 16.19 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $626.04 Million | $675.12 Million | $754.20 Million |
Abcellera Biologics Inc - Advanced Valuation Insights
This section examines the relationship between Abcellera Biologics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.78 |
| Latest Market Cap to Assets Ratio | 2.60 |
| Asset Growth Rate (YoY) | -0.3% |
| Total Assets | $1.36 Billion |
| Market Capitalization | $3.53 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Abcellera Biologics Inc's assets at a significant premium (2.60x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Abcellera Biologics Inc's assets decreased by 0.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Abcellera Biologics Inc (2018–2025)
The table below shows the annual total assets of Abcellera Biologics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.36 Billion | -0.26% |
| 2024-12-31 | $1.36 Billion | -8.57% |
| 2023-12-31 | $1.49 Billion | -3.43% |
| 2022-12-31 | $1.54 Billion | +16.86% |
| 2021-12-31 | $1.32 Billion | +31.13% |
| 2020-12-31 | $1.01 Billion | +4181.06% |
| 2019-12-31 | $23.49 Million | +9.29% |
| 2018-12-31 | $21.49 Million | -- |
About Abcellera Biologics Inc
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for… Read more